Physician profile
Danai Dima
NPI 1790270247
$8,334.20
in general payments reported to CMS, 2019-2025
27 companies · $4,139 in 2025
The $4,139 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2021: $523 · 2022: $1,104 · 2023: $1,373 · 2024: $900 · 2025: $4,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,777 · Food and Beverage: $2,703 · Education: $923 · Travel and Lodging: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,777.25 |
| Food and Beverage | $2,702.91 |
| Education | $923.39 |
| Travel and Lodging | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $2,828.72 | 2025 | Yescarta |
| Incyte Corporation | $827.23 | 2019-2024 | Jakafi, Monjuvi |
| Seagen INC. | $627.10 | 2021-2023 | Padcev |
| Pfizer INC. | $456.14 | 2024-2025 | |
| Janssen Biotech, INC. | $398.17 | 2023-2025 | Talvey, Tecvayli, Carvykti |
| Novartis Pharmaceuticals Corporation | $394.35 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $337.21 | 2025 | Xpovio |
| Astellas Pharma US INC | $321.54 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $285.94 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $274.29 | 2022-2025 | |
| Stemline Therapeutics INC. | $256.21 | 2024-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $197.63 | 2022-2023 | Ultomiris |
| Daiichi Sankyo INC. | $127.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $122.71 | 2022-2025 | Tecvayli, Darzalex, Carvykti |
| Amgen INC. | $120.00 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $116.40 | 2025 | Carvykti |
| Gilead Sciences, INC. | $116.10 | 2024 | Trodelvy |
| Jazz Pharmaceuticals INC. | $113.52 | 2021 | |
| Foundation Medicine, INC. | $96.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.00 | 2023 | |
| Genzyme Corporation | $81.17 | 2025 | |
| Lilly USA, LLC | $76.54 | 2023 | |
| Adaptive Biotechnologies Corporation | $56.28 | 2025 | Clonoseq |
| Btg International INC. | $14.81 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danai Dima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.